The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
Open accessAbstract
Background: Hyperactivation of the Ras signaling pathway is a driver of many cancers, and RAS pathway activation can predict response to targeted therapies. Therefore, optimal methods for measuring Ras pathway activation are critical. The main focus of our work was to develop a gene expression signature that is predictive of RAS pathway dependence. Methods: We used the coherent expression of RAS pathway-related genes across multiple datasets to derive a RAS pathway gene expression signature and generate RAS pathway activation scores in pre-clinical cancer models and human tumors. We then related this signature to KRAS mutation status and drug response data in pre-clinical and clinical datasets. Results: The RAS signature score is predictive of KRAS mutation status in lung tumors and cell lines with high (> 90%) sensitivity but relatively low (50%) specificity due to samples that have apparent RAS pathway activation in the absence of a KRAS mutation. In lung and breast cancer cell line panels, the RAS pathway signature score correlates with pMEK and pERK expression, and predicts resistance to AKT inhibition and sensitivity to MEK inhibition within both KRAS mutant and KRAS wild-type groups. The RAS pathway signature is upregulated in breast cancer cell lines that have acquired resistance to AKT inhibition, and is downregulated by inhibition of MEK. In lung cancer cell lines knockdown of KRAS using siRNA demonstrates that the RAS pathway signature is a better measure of dependence on RAS compared to KRAS mutation status. In human tumors, the RAS pathway signature is elevated in ER negative breast tumors and lung adenocarcinomas, and predicts resistance to cetuximab in metastatic colorectal cancer. Conclusions: These data demonstrate that the RAS pathway signature is superior to KRAS mutation status for the prediction of dependence on RAS signaling, can predict response to PI3K and RAS pathway inhibitors, and is likely to have the most clinical utility in lung and breast tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 Waterfall plot of RAS signature score in patients who experienced disease control (blue) or progressive disease (red) after Cetuximab therapy. The Y-axis shows RAS signature score relative to the mean of all tumors in this dataset. Fisher's exact test p-value for the difference between the disease control and progressive disease groups is shown. Data is derived from [5], and includes all patients with known response.](https://figures.cochat.ai/paper-figures/fd204e8c1d0b4e5fb7942859863890d2/a-gene-expression-signature-of-ras-pathway-dependence-predicts-response-to-pi3k-figure-6.jpg)
![Figure 7 RAS signature distribution across non-small cell lung (A) and breast (B) cancer subsets. The Y-axis shows RAS signature score relative to the mean of all non-small cell lung (A) or breast (B) tumors in the dataset. For (B), GGI = genomic grade index [32]. GGI- = ER positive, GGI negative (surrogate for luminal A). TN = triple negative. Her2 + = high expression of Her2. GGI + = ER positive, GGI high (surrogate for luminal B).](https://figures.cochat.ai/paper-figures/edc1fe3aa50147b6996f660202bffbc3/a-gene-expression-signature-of-ras-pathway-dependence-predicts-response-to-pi3k-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“supporting the notion that some KRAS-mutated CRC tumors are decoupled from RAS/MEK pathway activation [32]”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Genomic signatures to guide the use of chemotherapeutics
Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1491 · Cited by 593
RetractedA Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer
Potti, A., Mukherjee, S., Petersen, R., Dressman, H. K., Bild, A., Koontz, J., Kratzke, R., Watson, M. A., Kelley, M., Ginsburg, G. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060467 · Cited by 576
RetractedK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“For example, KRAS mutations are associated with decreased disease control rate, shorter progression-free survival and reduced overall survival in patients with advanced or metastatic colorectal cancer treated with the EGFR-targeting antibodies cetuximab or panitumumab [4-6].”
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 3×
“A gene expression signature-based pathway readout may be more appropriate than relying on a single indicator of pathway activity, as alterations in multiple signaling components could lead to pathway activation and result in similar downstream effects (for example, mutations in Braf also lead to pathway activation and…”
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer
Hughes, T. R., Mao, M., Jones, A. R., Burchard, J., Marton, M. J., Shannon, K. W., Lefkowitz, S. M., Ziman, M., Schelter, J. M., Meyer, M. R., et al. (2001) · Nature Biotechnology · doi:10.1038/86730 · Cited by 1,298
Self-citationThe PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Research works printed but not linked: 2
- Yan L: MK-2206: A potent oral allosteric AKT inhibitor. American Association for Cancer Research; April 19; Denver, CO. 2009
- Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al: Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. J Natl Cancer Inst. 2006, 98: 262-272. 10.1093/jnci/djj052. · DOI · Paper page
Cited by
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444
Schabath, M. B., Welsh, E. A., Fulp, W. J., Chen, L., Teer, J. K., Thompson, Z. J., Engel, B. E., Xie, M., Berglund, A. E., Creelan, B. C., et al. (2016) · Oncogene · doi:10.1038/onc.2015.375 · Cited by 416
An unbiased oncology compound screen to identify novel combination strategies
O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0843 · Cited by 407
Self-citation
Metadata
- Authors
- Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., Andersen, J., Nagashima, K., Paweletz, C., Lynch, B., Feldman, I., Dai, H., Huang, P., & Watters, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Watters, James
- ORCID
- Venue
- BMC Medical Genomics
- Published
- 2010-06-30
- Volume
- 3
- Issue
- 1
- Pages
- 26-26
- ISSN
- 1755-8794 (ISSN-L)
- PMC
- PMC2911390
- OpenAlex
- W2022577155
- Cited by
- 152
- References
- 30
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 11 · 2018: 12 · 2017: 14 · 2016: 14 · 2015: 12 · 2014: 14 · 2013: 10 · 2012: 13
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Medical Genomics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moffitt Cancer Center
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAS pathway activation, gene expression signatures, KRAS mutation status, PI3K inhibitors, MEK inhibitors, AKT inhibition, drug response prediction, lung cancer, breast cancer, lung adenocarcinoma, cetuximab resistance, colorectal cancer
- MeSH terms
- Cetuximab, Phosphoinositide-3 Kinase Inhibitors, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Inhibitors, Female, Humans, Lung Neoplasms, Mutation, Neoplasms, Proto-Oncogene Proteins, Colorectal Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Gene Expression Profiling, Mitogen-Activated Protein Kinase Kinases, Databases, Genetic, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. https://app.cochat.ai/papers/10.1186/1755-8794-3-26
- The paper
- Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., Andersen, J., Nagashima, K., Paweletz, C., Lynch, B., Feldman, I., Dai, H., Huang, P., & Watters, J. (2010). A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics. https://doi.org/10.1186/1755-8794-3-26
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.